Search

Mario Caccese,1 Silvia Imbevaro,2 Alessandra Feltrin,3 Daniela Costardi,4 Nadia Giordano,5 Maristella Maran,1 Rosalba Martino,1 Ketti Ottolitri,6 Malihe Shams,3 Federica Vascon,7 Anna Roma,5 Antonella Galiano,1 Marco Maruzzo,1 Dario Marino,1 Giuseppe Lombardi,1 Sara Lonardi,5 Antonella Brunello,1 Vittorina Zagonel1 1Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 2General Directorate, Accreditation and Acknowledgment Unit, Veneto Institute of Oncolog IOV - IRCCS, Padua, Italy; 3Health Department, Psycho-Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 4Scientific Directorate, Patient Education and Empowerment, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 5Department of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 6Health Department, Clinical Risk Office, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 7Department of Imaging and Health Physics, Radiotherapy Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, ItalyCorrespondence: Mario Caccese, Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata, 64, Padua, 35128, Italy, Email mario.caccese@iov.Veneto.itPurpose: The SARS-CoV-2 spread has impacted Healthcare systems. COVID-19 pandemic has had consequences for patients with cancer, being associated with delays in diagnosis, in treatment And follow-up care, increase in overall infection rates and higher mortality. A survey on COVID-19 and a vaccination-questionnaire were developed at different times of the outbreak, to evaluate cancer patient-reported experience measures (PREMs) on the policies implemented to reduce the infection from SARS-CoV-2 and on the timing and methods of COVID-19 vaccination.Patients and Methods: The survey was distributed to all patients accessing the Institute during the “first-wave” Of the pandemic, evaluating patients’ concerns about the pandemic, the pandemics’ consequences

1. BACKGROUND Hodgkin Lymphoma (HL) is a rare disease and it account for almost 5% of all malignant neoplasia and for 11% of lymphoma subtypes. Classical Hodgkin Lymphoma is hystologically characterized by the presence of giant multinucleated cells called Hodgkin cells and Reed-Sternberg cells: these are outnumbered respect to all cellular population in the neoplastic lymph node (about 1% to 5%) and are surrounded by a polymorphic reactive microenvironment constituted by lymphocytes, plasma cells, neutrophils, eosinophils, mast cells, macrophages, stromal cells and fibroblasts. Modern chemotherapy is able to cure about 80% of patients with Hodgkin Lymphoma. Because the disease occurs in young adulthood (age 15–35), there is a long life expectation so that the progressive improvement of cure rates must also taking into account the vital importance of long-term follow-up. Prognostic factors in patients include bulky mediastinal mass, B symptoms, more than 3 lymphatic stations involved and ESR > 50 mm/h. A multicentre study by Hasenclever et al. in 1998 identified seven prognostic factors for advanced stage HL (International Prognostic Score, IPS): age ≥ 45, gender, albumin < 40 g/L, hemoglobin < 105 g/L, stage, leukocytosis ≥ 15,000 per mm3 , lymphopenia. An early response assessment as measured by an interim PET/computed tomography (PET/CT) scan has been shown to be a very powerful prognostic tool that is independent of clinical and biologic prognostic factors, including the IPS. However, currently, at least 20% of patients relapsed and a similar proportion is over treated. Interim PET has a clinical value only after ABVD treatment while IPS score is validated only for advanced stage. Some authors reported a prognostic impact of Tumour Associated Macrophages (TAM) and of absolute lymphocyte/monocyte ratio in peripheral blood in classical Hodgkin Lymphoma at diagnosis. These studies provide conflicting results and analysis are often based on not homogeneous p

In this paper, we propose a decentralized coordina- tion algorithm for safe and efficient management of a group of mobile robots following predefined paths in a dynamic industrial environment. The proposed algorithm is based on a shared resources protocol and a replanning strategy. It is proved to guarantee ordered traffic flows avoiding collisions, deadlocks (stall situations) and livelock (agents move without reaching final destinations). Mutual access to resources has been proved for the proposed approach while condition on the maximum number of AGVs is given to ensure the absence of deadlocks during system evolutions. Finally conditions to verify a local livelocks will also be proposed. In consistency with the model of distributed robotic systems (DRS), no centralized mechanism, synchronized clock, shared memory or ground support is needed. A local inter-robot communication, based on sign-boards, is considered among a small number of spatially adjacent robotic units.